Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote insulin secretion and regulate blood glucose levels. Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. In clinical trials, vildagliptin has a relatively low risk of hypoglycemia.
Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with metformin, a sulfonylurea, or a thiazolidinedione in patients with inadequate glycemic control following monotherapy. It is marketed as Galvus. Vildagliptin is also available as Eucreas, a fixed-dose formulation with metformin for adults in who do not adequately glycemic control from monotherapy. Vildagliptin is currently under investigation in the US.
Vildagliptin is indicated in the treatment of type II diabetes mellitus in adults. As monotherapy, vildagliptin is indicated in adults inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. It is also indicated as dual therapy in combination with metformin, a sulphonylurea, or a thiazolidinedione in adults patients with insufficient glycemic control despite maximal tolerated dose of monotherapy.
Vildagliptin is also marketed in a combination product with metformin for the treatment of adults with type II diabetes mellitus who inadequately respond to either monotherapy of vildagliptin or metformin. This fixed-dose formulation can be used in combination with a sulphonylurea or insulin (i.e., triple therapy) as an adjunct to diet and exercise in adults who do not achieve adequate glycemic control with monotherapy or dual therapy.
Hospital de la Ribera, Alzira, Spain
Hospital San Pedro de Alcantara, Caceres, Spain
Clinica Mediterranea de Neurociencias, Alicante, Spain
Novartis Investigator Site, Berlin, Germany
Novartis Investigator Site, Baltimore, Maryland, United States
Baylor College of Medicine, Houston, Texas, United States
University of Cincinnati, Cincinnati, Ohio, United States
Anasazi Internal Medicine, Phoenix, Arizona, United States
Novartis Investigator Site, Kiel, Germany
Novartis Investigator Site, Kiel, Germany
Novartis Investigative Site, Bochum, Germany
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Novartis Investigative Site, Multiple Locations, Germany
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.